Price
No data yet.
Social Signal Score
Analyst Ratings
34 analystsRevenue
$173.00M+3459900.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Emil D. Kakkis
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,371
- Beta
- 0.32
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -5.65
Financials
Revenue
$173.00M+3459900.0%Net Income
$-118.00MEBITDA
$-101.00MFree Cash Flow
$-45.00MEPS (diluted)
$-1.16Shares Outstanding (diluted)
102.10M+150.3%Operating Expenses
$251.00MCash & Debt
$266.00MRevenue by Segment (annual)
$673.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $673.00M | $-575.00M | $-5.83 |
| 2024 | $560.23M | $-569.18M | $-6.29 |
| 2023 | $434.25M | $-606.64M | $-8.25 |
| 2022 | $363.33M | $-707.42M | $-10.12 |
| 2021 | $351.41M | $-454.02M | $-6.70 |
| 2020 | $271.03M | $-186.57M | $-3.07 |
| 2019 | $103.71M | $-402.73M | $-7.12 |
| 2018 | $51.49M | $-197.61M | $-3.97 |
| 2017 | $2.61M | $-302.14M | $-7.12 |
| 2016 | $133.0K | $-245.87M | $-6.21 |
| 2015 | $0.00 | $-145.62M | $-3.96 |
| 2014 | $0.00 | $-59.80M | $-2.08 |
| 2013 | $0.00 | $-35.07M | $-1.21 |
| 2012 | $0.00 | $-16.33M | $-0.71 |
Valuation
RAREhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
93+211.11%Social Signal Score
Mentions (37)
- Newsseekingalpha.com·5d ago·Positive
Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Transcript Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - Newsmarketbeat.com·5d ago·Neutral
Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches Ultragenyx Pharmaceutical NASDAQ: RARE expects to reach profitability in 2027 as it cuts spending, expands sales of existing rare-disease treatments and launches two gene therapies, executives said at the UBS Global Biopharma Conference.
View source ↗ - Newsglobenewswire.com·11d ago·Neutral
Ultragenyx to Participate at Investor Conferences in London NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in upcoming investor conferences.
View source ↗ - Newsseekingalpha.com·18d ago·Neutral
Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot Ultragenyx Pharmaceutical remains a cautious 'Hold,' as profitability targets are driven by deep R&D cuts, not robust revenue growth. RARE's Q3 revenue rose 8% Y/Y to $173M, but business remains highly concentrated in CRYSVITA, with new launches contributing minimally. Pipeline setbacks and terminated programs have forced a pivot from high-risk optionality to a leaner rare-disease commercial model.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CEO & Director Howard Horn - Executive VP of Corporate Strategy & CFO Erik Harris - Executive VP & Chief Commercial Officer Eric Crombez - Chief Medical Officer & Executive VP Conference Call Participants Mauric…
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call Ultragenyx Pharmaceutical NASDAQ: RARE said its third quarter included two U.S. gene therapy approvals, a failed late-stage Angelman syndrome study, the termination of its Wilson disease program and restructuring actions intended to support GAAP profitability in 2027.
View source ↗ - Newszacks.com·19d ago·Negative
Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates Ultragenyx (RARE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $1.81 per share a year ago.
View source ↗ - Newszacks.com·19d ago·Negative
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newsglobenewswire.com·19d ago·Negative
…ay, expected to drive at least a 50% reduction in 2027 R&D expenses vs 2025 NOVATO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2026, announced substantial expense reductions, and reaffirmed its guidance for 2026 revenue and 2027 profit…
View source ↗ - Newszacks.com·26d ago·Neutral
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newszacks.com·38d ago·Negative
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.
View source ↗ - Newszacks.com·39d ago·Neutral
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.
View source ↗ - Newsglobenewswire.com·39d ago·Negative
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million Agreement marks the Company's second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction Agreement marks the Company's second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction
View source ↗ - Newszacks.com·45d ago·Negative
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.
View source ↗ - Newsproactiveinvestors.com·46d ago·Negative
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million Ultragenyx Pharmaceutical (NASDAQ:RARE) shares rose over 3.2% on Wednesday morning after the biopharmaceutical company agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The voucher was awarded to Ultragenyx after the US Food and Drug Administration approved GENGLYCOS, also known as DTX401, for glycogen storage disease (GSD) type Ia.
View source ↗ - Newsglobenewswire.com·46d ago·Negative
…ent to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. Ultragenyx received the PRV upon U.S. Food and Drug Administration (FDA) approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, the first treatment designed t…
View source ↗ - Newszacks.com·48d ago·Neutral
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.
View source ↗ - Newsprnewswire.com·59d ago·Negative
JAGUAR URANIUM REPORTS RARE EARTH OXIDES ASSOCIATED WITH URANIUM-PHOSPHATE-VANADIUM MINERALIZATION AT THE BERLIN ASSET IN COLOMBIA Selected retained-core intervals contain rare earth elements, including neodymium, praseodymium, terbium and dysprosium (magnet rare earths), together with uranium, vanadium and phosphate mineralization. 0.63 m @ 3,570 ppm TREO (0.357%) and 607 ppm MREO, the highest TREO value reported from the selected intervals in this resampling program.
View source ↗ - Newsglobenewswire.com·61d ago·Negative
ULTRA-RARE MCA CENTENAIRE, MONACO'S FIRST SUPERCAR, OFFERED AT BROAD ARROW'S 2026 ZOUTE CONCOURS AUCTION Monte Carlo Automotive (MCA) Centenaire was the first road car with a carbon fibre monocoque chassis and is powered by a 5.2-litre V12 from the Lamborghini Countach 5000 QV | This example of Monaco's first supercar, created in partnership with Lamborghini, is the first of just five Centenaire models produced | Originally retained by the Lamborghini factory and displayed at Rétromobile 2007, t…
View source ↗ - Newszacks.com·65d ago·Neutral
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.
View source ↗ - Newszacks.com·65d ago·Positive
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains? Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
View source ↗ - Newsseekingalpha.com·65d ago·Positive
Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript
View source ↗ - Newsglobenewswire.com·66d ago·Negative
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA) FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type A
View source ↗ - Newsreuters.com·66d ago·Negative
US FDA approves Ultragenyx's gene therapy for rare disorder The U.S Food and Drug Administration said on Thursday it has approved Ultragenyx's gene therapy for the treatment of a rare, fatal disease.
View source ↗ - Newszacks.com·80d ago·Neutral
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report? Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsbarrons.com·80d ago·Negative
Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving Up Yet. Ultragenyx Pharmaceuticals looks to cut costs following the trial failure, while attention remains squared on its burgeoning commercial business.
View source ↗ - Newsreuters.com·80d ago·Negative
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial Shares of Ultragenyx Pharmaceutical plunged more than 40% in premarket on Thursday after its neurodevelopmental disorder treatment failed a closely watched late-stage trial, dealing a major blow to one of its biggest growth bets.
View source ↗ - Newsreuters.com·81d ago·Negative
Ultragenyx's rare disease drug fails in late-stage trial; shares plunge Ultragenyx Pharmaceutical said on Wednesday its experimental drug for a rare genetic neurodevelopmental disorder did not meet the main goal in a late-stage trial, sending its shares down 40% in aftermarket trading.
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome Phase 3 Aspire did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI)
View source ↗ - Newsglobenewswire.com·82d ago·Negative
Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease At Week 96, participants across treatment and crossover groups experienced mean reduction in daily cornstarch intake of 61% while maintaining glycemic control, with most participants achieving reduction of at least 50%
View source ↗ - Newszacks.com·94d ago·Positive
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting the underlying cause of GSDIa, boosting its rare-disease portfolio.
View source ↗ - Newsbenzinga.com·94d ago·Negative
Ultragenyx Nabs FDA Nod for First Gene Therapy Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares are up during Thursday's premarket session on the recent U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy, Genglycos (pariglasgene brecaparvovec-opnr, or DTX401).
View source ↗ - Newsmarketbeat.com·94d ago·Negative
Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy Ultragenyx Pharmaceutical NASDAQ: RARE said the U.S. Food and Drug Administration has approved GENGLYCOS, also known as DTX401, for glycogen storage disease type 1A, or GSD1A. The approval marks the company's first gene therapy approval and its fifth approved medicine.
View source ↗ - Newsseekingalpha.com·94d ago·Positive
Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a Transcript Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a Transcript
View source ↗ - Newsreuters.com·95d ago·Negative
Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod The U.S. Food and Drug Administration approved Ultragenyx Pharmaceutical's gene therapy to treat a rare metabolic disorder, the company said on Wednesday.
View source ↗ - Newsglobenewswire.com·95d ago·Neutral
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to reduce the burden of care associated with GSDIa Ultragenyx received a Priority Review Voucher upon approval Ultragenyx to host conference call on 8/19/26 at 6:00 p.
View source ↗ - Newsseekingalpha.com·100d ago·Positive
Ultragenyx: Undervalued Ahead Of Two FDA Decisions Ultragenyx Pharmaceutical is rated a soft Buy at $26.75, with a probability-weighted fair value of ~$32 per share. Two near-term FDA decisions: DTX401 on Aug 23 and another for UX111 on Sept 19. DTX401 has a cleaner regulatory case, but UX111 has a credible approval path. Using 80% approval odds for DTX401 and 65% for UX111, our probability-weighted value is approximately $32 per share versus a current share price near $27.
View source ↗
Earnings
Thu, Feb 11(in 3 months)
Consensus estimate $2.37 per share
Typical surprise -5.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$-1.16 vs $-1.10miss
- Tue, Aug 4$-0.90 vs $-1.22beat
- Tue, May 5$-1.84 vs $-1.49miss
- Thu, Feb 12$-1.29 vs $-1.20miss
- Tue, Nov 4$-1.81 vs $-1.23miss
- Tue, Aug 5$-1.17 vs $-1.27beat
Estimates and results for RARE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RARE officers and directors.
- Bought
- —
- Sold
- $5.5m
0 trades
39 trades
- Horn Howardsold
- Huizenga Theodore Alansold
- Huizenga Theodore Alansold
- Parschauer Karah Herdmansold
- Horn Howardsold
- Horn Howardsold
- Sanders Corazon (corsee) D.sold
- Parschauer Karah Herdmansold
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Oct 12, 2026 (13d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Mar 10, 2026 (20d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Sep 12, 2025 (35d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Aug 15, 2025 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 8, 2022 (18d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 8, 2022 (28d later)Sell$1,001 - $15,000
- Kurt Schraderhouse · OR05 · disclosed Sep 8, 2021 (9d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
